1. Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.
- Author
-
Stefanou, Maria Ioanna Karachaliou, Eleni Chondrogianni, Maria Moschovos, Christos Bakola, Eleni Foska, Aikaterini Melanis, Konstantinos Andreadou, Elisabeth Voumvourakis, Konstantinos Papathanasiou, Matilda Boutati, Eleni Tsivgoulis, Georgios and Stefanou, Maria Ioanna Karachaliou, Eleni Chondrogianni, Maria Moschovos, Christos Bakola, Eleni Foska, Aikaterini Melanis, Konstantinos Andreadou, Elisabeth Voumvourakis, Konstantinos Papathanasiou, Matilda Boutati, Eleni Tsivgoulis, Georgios
- Abstract
This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.
- Published
- 2022